Overview of Safety Pharmacology

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Current Protocols in Pharmacology

• Publication date

  2013-12-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1002/0471141755.ph1001s63PMID 24510755
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Functional assessments in repeat-dose toxicity studies: the art of the possible

  2013cited by this paper
• Supplemental Studies for Cardiovascular Risk Assessment in Safety Pharmacology: A Critical Overview

  2011cited by this paper
• How Good Are Current Approaches to Nonclinical Evaluation of Abuse and Dependence?

  2011cited by this paper
• Respiratory inductive plethysmography as a method for measuring ventilatory parameters in conscious, non-restrained dogs.

  2010cited by this paper
• Ventilatory function assessment in safety pharmacology: optimization of rodent studies using normocapnic or hypercapnic conditions.

  2010cited by this paper
• Principles of Safety Pharmacology

  2008cited by this paper
• CNS Safety Pharmacology

  2008cited by this paper
• The use of the dog electroencephalogram (EEG) in safety pharmacology to evaluate proconvulsant risk.

  2007cited by this paper
• Comprehensive non-clinical respiratory evaluation of promising new drugs.

  2005cited by this paper
• Pentamidine-Induced Long QT Syndrome and Block of hERG Trafficking

  2005cited by this paper
• International safety pharmacology guidelines (ICH S7A and S7B): where do we go from here?

  2005cited by this paper
• DPI-3290 [(+)-3-((α-R)-α-((2S,5R)-4-Allyl-2,5-dimethyl-1-piperazinyl)-3-hydroxybenzyl)-N-(3-fluorophenyl)-N-methylbenzamide]. I. A Mixed Opioid Agonist with Potent Antinociceptive Activity

  2003cited by this paper
• DPI-3290 [(+)-3-((alpha-R)-alpha-((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3-hydroxybenzyl)-N-(3-fluorophenyl)-N-methylbenzamide]. I. A mixed opioid agonist with potent antinociceptive activity.

  2003cited by this paper
• DPI-3290 [(+)-3-((α-R)-α-((2S,5R)-4-Allyl-2,5-dimethyl-1-piperazinyl)-3-hydroxybenzyl)-N-(3-fluorophenyl)-N-methylbenzamide]. II. A Mixed Opioid Agonist with Potent Antinociceptive Activity and Limited Effects on Respiratory Function

  2003cited by this paper
• Assessment of respiratory function in safety pharmacology

  2002cited by this paper
• Basic safety pharmacology: the cardiovascular system.

  2000cited by this paper
• Comparative study of TA-606, a novel angiotensin II receptor antagonist, with losartan in terms of species difference and orthostatic hypotension.

  1999cited by this paper
• Status of safety pharmacology in the pharmaceutical industry—1995

  1995cited by this paper
• Respiratory effects of morphine in awake unrestrained rats.

  1986cited by this paper

• Respiratory safety pharmacology study of single oral administration of pentoxifylline in Sprague-Dawley rats

  2025cites this paper
• Preclinical Safety Profile of Deg-AZM, a Clinical-Stage New Transgelin Agonist: hERG Inhibition Study In Vitro, Cardiovascular–Respiratory Pharmacology, and Single/Repeated-Dose Toxicity in Beagle Dogs

  2025cites this paper
• Comprehensive approaches to preclinical evaluation of monoclonal antibodies and their next-generation derivatives.

  2024cites this paper
• Safety Pharmacology

  2022cites this paper
• Safety assessment of HEA‐enriched Cordyceps cicadae mycelia on the central nervous system (CNS), cardiovascular system, and respiratory system in ICR male mice

  2021cites this paper
• Safety Pharmacological studies of Kalyanaka ghrita

  2021cites this paper
• When pharmaceutical drugs become environmental pollutants: Potential neural effects and underlying mechanisms.

  2021cites this paper
• In Silico Trials for Drug Safety and Efficacy Assessment Using a Novel Human Purkinje Fibre Model

  2020cites this paper
• The role of fMRI in drug development.

  2018cites this paper
• Inhibition of the α-Subunit of Phosphoinositide 3-Kinase in Heart Increases Late Sodium Current and Is Arrhythmogenic

  2018cites this paper
• GABA-A and GABA-B Receptors in Filial Imprinting Linked With Opening and Closing of the Sensitive Period in Domestic Chicks (Gallus gallus domesticus)

  2018cites this paper
• Nonclinical Safety Pharmacology

  2018cites this paper
• Inhibition of the α-subunit of phosphoinositide 3-kinase (PI3K) in heart increases late sodium current and is arrhythmogenic

  2018cites this paper
• Preclinical safety assessments of nano‐sized constructs on cardiovascular system toxicity: A case for telemetry

  2017cites this paper
• Effect of Wearing a Telemetry Jacket on Behavioral and Physiologic Parameters of Dogs in the Open-Field Test.

  2017cites this paper
• Evidence for Tonic Control by the GABAA Receptor of Extracellular D-Serine Concentrations in the Medial Prefrontal Cortex of Rodents

  2017cites this paper
• Preclinical Pharmacology and Toxicology - Contributions to the Translational Interface

  2014cites this paper
• Optimized Nonclinical Safety Assessment Strategies Supporting Clinical Development of Therapeutic Monoclonal Antibodies Targeting Inflammatory Diseases

  2014cites this paper
• Translational paradigms in pharmacology and drug discovery.

  2014cites this paper